BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

14:00 - 14:30
Satellite Symposium – Roche
Oral Selective Estrogen Receptor Degraders (SERDs): Emerging Treatment Option for HR +ve Breast Cancer
Chairperson: YAP YOON SIM, SINGAPORE
Speaker: ELGENE LIM, AUSTRALIA

14:30 – 14:45
Basic / Translational Science
Speaker: ELGENE LIM, AUSTRALIA
• GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial
• GS1-10: Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST
• GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

14:45 – 15:05
Early Breast Cancer ER Positive HER2 Negative
Speaker: VIRGINIA KAKLAMANI, USA
• GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early-stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
• GS2-05: Randomized comparison of adjuvant exemestane + OFS vs tamoxifen plus OFS in premenopausal women with HR+ early breast cancer: update of the combined TEXT and SOFT trials
• GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes, hormone receptor-positive (HR+) and HER2-negative breast cancer with recurrence score of 25 or less: SWOG S1007

15:05 – 15:15
Early Breast Cancer Adjuvant/Neoadjuvant Therapy
Speaker: TIRA TAN, SINGAPORE
• GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials
• GS1-02: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
15:15 – 15:25
Local Therapy
Speakers: VERONIQUE TAN, SINGAPORE | FAYE LIM, SINGAPORE

• GS4-05: Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One

15:25 – 15:45
Advanced Breast Cancer ER Positive HER2 Negative
Speaker: SHAHEENAH DAWOOD, UAE

• GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer
• GS3-05: Results of PADA-1- Fulvestrant-palbociclib vs continuing AI-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2 negative metastatic breast cancer
• GS2-02: Elacestrant, an oral SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
• GS3-010: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

15:45 – 16:00
Advanced Breast Cancer Triple Negative/HER2 Positive/Immunotherapy
Speaker: WONG NAN SOON, SINGAPORE

• GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
• GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
• GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
• GS51-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

2022 VIRTUAL SUMMIT
Sunday, 6th MARCH 2022
14:00 - 16:00 Singapore Time

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

15:15 – 15:25
Local Therapy
Speakers: VERONIQUE TAN, SINGAPORE | FAYE LIM, SINGAPORE

• GS4-05: Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One

15:25 – 15:45
Advanced Breast Cancer ER Positive HER2 Negative
Speaker: SHAHEENAH DAWOOD, UAE

• GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer
• GS3-05: Results of PADA-1- Fulvestrant-palbociclib vs continuing AI-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2 negative metastatic breast cancer
• GS2-02: Elacestrant, an oral SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
• GS3-010: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

15:45 – 16:00
Advanced Breast Cancer Triple Negative/HER2 Positive/Immunotherapy
Speaker: WONG NAN SOON, SINGAPORE

• GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
• GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
• GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
• GS51-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

15:15 – 15:25
Local Therapy
Speakers: VERONIQUE TAN, SINGAPORE | FAYE LIM, SINGAPORE

• GS4-05: Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodar One

15:25 – 15:45
Advanced Breast Cancer ER Positive HER2 Negative
Speaker: SHAHEENAH DAWOOD, UAE

• GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer
• GS3-05: Results of PADA-1- Fulvestrant-palbociclib vs continuing AI-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2 negative metastatic breast cancer
• GS2-02: Elacestrant, an oral SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
• GS3-010: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

15:45 – 16:00
Advanced Breast Cancer Triple Negative/HER2 Positive/Immunotherapy
Speaker: WONG NAN SOON, SINGAPORE

• GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03
• GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
• GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)
• GS51-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study